3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
2
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
93
Carcinoma, Non-Small-Cell Lung
46
Neoplasms
33
Carcinoma, Renal Cell
24
Neoplasm Metastasis
16
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
12
Small Cell Lung Carcinoma
9
Prostatic Neoplasms
9
Lung Neoplasms
9
Diabetes Mellitus, Insulin-Dependent, 12
9
Advanced Cancer
9
Squamous Cell Carcinoma of Head and Neck
8
Uveal Melanoma
7
Stomach Neoplasms
7
Skin Neoplasms
7
Mesothelioma
7
Kidney Neoplasms
7
Carcinoma, Transitional Cell
7
Recurrence
6
Pancreatic Neoplasms
6
Liver Neoplasms
6
Triple Negative Breast Neoplasms
5
Sarcoma
5
Ovarian Neoplasms
5
Head and Neck Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Solid Tumor
4
Interventions
Gemcitabine
12
Cisplatin
11
pembrolizumab
6
Docetaxel
5
Capecitabine
5
camrelizumab
4
Injections
4
toripalimab
3
spartalizumab
3
penpulimab
2
famitinib
2
SHR-1701
2
Carboplatin
2
18-O-demethylcervinomycin A2
2
tislelizumab
1
icotinib
1
donafenib
1
cc-486
1
Valganciclovir
1
Radiotherapy, Intensity-Modulated
1
Quality of Life
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Medicare Part B
1
Ipilimumab
1
Immunotherapy
1
Fluorouracil
1
Drug Therapy
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Nasopharyngeal Carcinoma
×
Ipilimumab
×
Clear all
NCT03752398
2024-07-05
DUET-3
Xencor, Inc.
Phase 1
Completed
198 enrolled